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Abstract In the future, stroke patients may receive stem cell therapy as this has the potential 
to restore lost functions. However, the development of clinically deliverable therapy has been 
slower and more challenging than expected. Despite recommendations by STAIR and STEPS 
consortiums, there remain flaws in experimental studies such as lack of animals with 
comorbidities, inconsistent approaches to experimental design and concurrent rehabilitation 
that might lead to a bias towards positive results. Clinical studies have typically been small, 
lacking control groups, often without clear biological hypotheses guiding patient selection 
and furthermore, they have used a wide range of cell types, doses and delivery methods, and 
outcome measures have been inconsistent. Fortunately, some ongoing and recent trial 
programs offer hints that these obstacles are now being tackled. The Horizon2020 funded 
RESSTORE trial will be given as an example of inconsistent regulatory requirements and 
challenges in harmonized cell production, logistic and clinical criteria in an international 
multicenter study. The PISCES trials highlight the complex issues around intracerebral cell 
transplantation. Therefore, a better understanding of translational challenges is expected to 
pave the way to more successful help for stroke patients. 
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Introduction 
After the acute stage, the therapeutic options for stroke are limited, and despite important 
advances in acute reperfusion treatments, systems of care, and secondary prevention, a high 
proportion of patients remain disabled after their stroke (1). Thus, restorative approaches 
including cell therapies have been heralded as the future therapy for this devastating 
condition (2). Since it has been claimed that cell therapies offer a wider therapeutic time 
window, they might be available for a larger number of patients and allow combination with 
other rehabilitative strategies.  
Two distinct strategies for cell therapy have emerged from animal data. The first is a 
neuroprotectant strategy, using systemically delivered (typically intravenously administered) 
cells to limit the evolution of the early brain injury (3,4). The mechanism of action appears to 
be reliant on “bystander” effects; these are likely to include immunomodulatory and anti-
inflammatory effects mediated via the systemic release of trophic factors (5), since neither 
animal nor human data have found any signs of actual engraftment of intravenously delivered 
cells in the brain (6–8).  
The second strategy utilizes cell regeneration or replacement to promote recovery 
during the later stages after stroke. This usually involves cell delivery to the site of injury by 
intraparenchymal brain implantation, usually involving stereotaxic injection into unaffected 
deep brain structures adjacent to the site of injury. A somewhat less invasive delivery has 
exploited an intra-arterial approach; this has been associated with some persistence of 
limited quantities of cells  in the central nervous system (6,9,10). It is unclear to what extent 
cells survive over the long term, the differentiation fate of surviving cells, or whether survival 
results in functional engraftment. The putative therapeutic effect in this paradigm may also 
rely on the release of trophic factors, promoting endogenous stem cell mobilization, and anti-
apoptotic effects in addition to the anti-inflammatory and immunomodulatory effects 
encountered after systemic cell delivery. The extent to which cells can migrate from their 
implantation site in human subjects is unclear. Placing cells within the cystic space left as a 
long-term consequence of ischemic damage, in the absence of some kind of bio-scaffold, will 
be unlikely to promote cell adherence or persistence. In addition, gliosis on the margins of 
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the damaged region may impede cell migration or axonal outgrowth in the same manner as 
encountered after spinal cord injury. 
This short review will address some preclinical issues inherent with stroke models, 
outcome measures and cell products, which may lead to an exaggeration of experimental 
results and eventually contribute to translational failure. Even before they are initiated, 
clinical trials are confronted by methodological, regulatory and financial challenges, possibly 
explaining the slow progress on the clinical side. This will be discussed in the light of the 
RESSTORE and PISCES trials.  
 
Promising Preclinical Evidence 
A large number of different cell preparations and delivery routes have been tested in both 
the preclinical and clinical settings (Table 1). Surprisingly, the therapeutic effect is not clearly 
influenced by cell type or delivery route, again suggesting that the cells secrete beneficial 
factors that can have immunomodulatory or anti-inflammatory effects. 
Preclinical evidence obtained with cell products appears to be extremely promising; 
the effects detected have included a decrease in infarct size and improved behavioral 
outcome (2,11). The therapeutic efficacy has been assessed in several meta-analyses (12–16). 
Both Lees et al. (12) and Chen et al. (14) concluded that stem cells appear to be of some 
benefit, but at the same time, they pointed out the poor study quality and publication bias. 
In contrast, another meta-analysis stated that mesenchymal stromal cells had been effective 
in 44 out of 46 studies (13). Frankly, one may ask whether this is too good to be true.  
Nevertheless, the promising experimental data have prompted early phase studies in 
stroke patients, which have provided preliminary data on safety and feasibility (17), although 
with some major limitations. Many of these studies have been small and underpowered to 
reveal true statistically significant treatment effects (18). In addition, a recent survey 
identified only 9 studies that had included a control group of any kind to allow evaluation of 
treatment effects (19). Thus, larger, randomized and controlled studies are urgently 
warranted to prove therapeutic efficacy.  
 
Importance of Comorbidities - Missed Lesson from Neuroprotection Studies 
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The experimental literature gives the impression that cell therapy should be effective in 
improving behavioral recovery after stroke (13,16). However, the critical evaluation of 
experimental research has been limited (20). Experimental cell therapy research suffers from 
many technical and methodological limitations as described for acute neuroprotection 
(21,22), deficiencies which were initially highlighted in the Stroke Therapy Academic-Industry 
Roundtable (STAIR) meetings. These sessions had been established when translational 
failures had accumulated, and subsequently, were the reason for adopting the meta-analysis 
approach to animal studies. Recently significant improvement has been reported in stroke 
study quality (23) although some basic issues such as use of anesthesia have not changed over 
the years (24).  
 Typically, experimental stroke studies are planned to ensure consistency in lesion size 
and location which hopefully will translate into a standardized behavioral impairment. This 
allows the use of minimal number of animals not only helping to keep study costs within 
limited budgets but also adhering to the appropriate ethical principles. However, stroke 
patients are a heterogeneous population  with regard to pathology, mechanism, lesion size 
and location, and clinical background, typically having comorbidities and being treated with 
polypharmacy and co-interventions (18). Thus, homogeneity in experimental animals is likely 
to over-estimate the treatment effect size compared to that likely to be achieved in clinical 
trials.  
Comorbidities such as ageing, hypertension and diabetes were recognized by both 
STAIR (25) and STEPS 2 (26) committees as potentially important confounding factors in 
stroke research. More importantly, ignoring common comorbidities may explain, at least 
partly, failures with neuroprotective drugs (27) although the extent to which these 
comorbidities might affect therapeutic effects is unclear. For example, if a therapeutic 
intervention has a different magnitude (or indeed direction) of effect in the face of these 
comorbidities, then this may be compensated for by increasing sample size, or by applying 
selection criteria in clinical phase 2 trials. However, this is only possible if the influence of 
potential confounders is understood. It has been argued that cell-based therapies should 
routinely be evaluated in animals with some comorbid disease, although this complicates 
study design, increases sample sizes, and prolongs the preclinical investigation phase of 
potential treatments. Ultimately, the clinical relevance of animal model findings may itself be 
uncertain, but identification of possible issues may at least allow for modification of the 
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clinical study design. In one example, of an unexpected interaction, bone marrow derived 
stem cells, which were shown to promote functional outcome after stroke in nondiabetic rats 
(28,29), increased mortality, blood-brain barrier leakage and incidence of hemorrhage in 
streptozotocin-treated rats, a model mimicking type 1 diabetes (30). Although these 
complications were not seen in a type 2 diabetes model (31), it emphasized the need for 
caution as well as the benefits of including confounding factors in study design.   
In addition to comorbid conditions, non-modifiable risk factors such as age and sex 
should be considered for evaluation. Although highly clinically relevant, this might be 
challenging due to higher mortality and variability in outcomes (32). Since it is unlikely that all 
potentially relevant models would be available in a single laboratory, collaborative pre-clinical 
multicentre projects utilizing a range of models could be undertaken both as an academic 
collaboration and as a commercial approach that would also strengthen confidence in data 
and provide a more robust estimate of likely effect sizes (33). The first trials with independent 
academic centers have proven the feasibility of adopting such a coordinated approach (34).   
 
Rehabilitation as a Translational Gap in Experimental Studies 
Rehabilitation is another issue not often incorporated into current experimental research. 
Most stroke survivors receive rehabilitation in one form or another, but this is rarely included 
in experimental study designs. The importance of rehabilitation has been included in STEPS 3 
recommendations (35).  
Modelling voluntary rehabilitative training in rodents is challenging. Motivating 
animals without reward or imposing extra stress, which may mask the treatment effect, is 
challenging. Various approaches such as special rehabilitative training devices (36), forced use 
of a forelimb (37) and acrobatic training (38) have been introduced. The first two mimic 
constraint-induced movement therapy of the upper extremity in stroke patients (39). Housing 
in an enriched environment has also been used to model non-specific rehabilitative training 
with sensory, motor, social and visual stimuli (40). Compared to an enriched environment, 
housing in a “standard environment” means less activity and social stimuli for the 
experimental animals. One extremity is social isolation by single housing, which may worsen 
infarct size and outcome (41). The importance of housing partners is emphasized by the 
recent study showing improved behavioral recovery, when ischemic animals were housed 
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together with healthy animals (42). Since social interactions have an impact on histological 
and functional outcome after experimental stroke (43), the housing conditions should be 
carefully reported in stroke recovery studies as recommended in the ARRIVE guidelines (44). 
The treatment contrast between cell and control groups can be easily increased by selecting 
appropriate housing for the experimental animals. 
Only limited evidence is available on the role of rehabilitative training in stroke 
recovery studies. Cell therapy seems to be more effective when combined with housing in an 
enriched environment. The behavioral improvement detected in the cylinder test measuring 
spontaneous forelimb use was associated with increased cell survival and migration and 
enhanced neurogenesis in cell-treated rats (45). Nonetheless, the animals’ performance in 
the more demanding Montoya’s staircase test did not show a treatment effect (46). Treadmill 
exercise enhanced the therapeutic potency of bone marrow-derived mesenchymal stem cells 
given intravenously, possibly through inhibiting apoptosis in the perilesional cortex (47). The 
combination of physical exercise and intravenous infusion of bone marrow derived 
mesenchymal stem cells exerted a synergistic effect after stroke in rats (48). The higher limb-
placing scores in the combined therapy group were associated with a greater density of 
synaptic markers and more extensive white matter changes. Thus, it seems that rehabilitative 
training may augment the same brain repair mechanisms as cell therapy or other restorative 
therapies, leading to some degree of synergistic functional improvement. 
The problem in the above studies and in the assessment of rodent behavior in general 
is compensatory movement strategies that stroke animals develop to complete a given task 
(49). Kinematic analysis is the only way to exclude compensation. For example, the pellet 
reaching task measures the success rate and/or number of pellets retrieved, but it also allows 
a more detailed analysis of movement patterns. By using kinematic analysis, Knieling et al. 
(50) demonstrated that although the success rate had improved in stroke animals housed in 
an enriched environment, this was due to compensatory movement strategies. Similarly, in 
stroke patients, a recent study revealed that improvement after constraint-induced 
movement therapy appears to be mediated through compensatory strategies rather than 
actual restoration of pre-stroke movement patterns (51). Kinematic analysis was also applied 
to study motor recovery in stroke rats treated with bone marrow derived stem cells (52). The 
cell-treated group showed improved forelimb functions which more closely resembled pre-
stroke movement patterns. 
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There is an ongoing debate about whether the combination of various rehabilitative 
strategies has a synergistic and beneficial effect in stroke recovery but more and more 
evidence suggests that this is the case (45,46,48). Therefore, to mimic the clinical situation, 
testing of cell therapies should ideally include rehabilitation for sensorimotor function 
whenever possible, although the relevance of rehabilitative strategies in rodent models to the 
human situation is somewhat unclear. 
 
From Proof-of-Concept Studies to Large Multicentre Trials 
Despite encouraging results from cell therapy in experimental stroke, few stroke patients 
have been included in proof-of-concept trials or pilot phase II trials, and very few studies have 
been randomized or have included a control group. The trials have employed a wide range of 
different cell types, delivery routes, time windows and outcome measures.  
Appropriate clinical populations, trial designs and end-points are likely to differ 
between systemic delivery of cells and intraparenchymal transplantation, although, to date, 
the boundaries have not been clearly demarcated in many small exploratory clinical studies 
(53). If one examines the 28 trials published from 2000 to 2017, only 10 studies were 
randomized and included a control group (a total of 261 patients and 251 controls) (Table 2). 
The validity of control groups is not always clear, since few studies undertook control 
strategies for factors such as placebo effects, or systematic differences in rehabilitation 
strategies. In a meta-analysis, cell therapy was associated with a positive effect independent 
of several explanatory variables (e.g., age, ratio of infarction/hemorrhage, delay from stroke 
to treatment, route of administration, cell type) (19). There was, however, substantial 
heterogeneity in the methodological and quality measures among these trials, and much 
larger, multicentre trials, will be necessary before any definitive conclusions can be made. 
Intravenous cell delivery in the early subacute stages after ischemic stroke has been 
investigated in two moderately-sized randomized trials, one using autologous bone marrow-
derived mononuclear cells (54), in 120 patients and the other administering allogeneic bone 
marrow-derived cells depleted of CD45 (+)/glycophorin-A (+) cells referred to as multipotent 
adult progenitor cells (MAPCs) (55) in 126 patients but neither of these trials detected 
significant impact on neurological recovery. Recruitment to the Athersys MASTERS trial was 
affected by requirements for cell lab processing of treatment doses, and the relaxation of 
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recruitment window to 48 hours instead of the initially planned 36 hours after stroke was 
considered to be a potential factor in failure to show efficacy (55). 
Intraparenchymal brain implantation of commercially developed allogeneic cells has 
undergone a preliminary investigation in two recent studies involving patients with severe 
disability 6-60 months after stroke (56,57). The Pilot Investigation of Stem Cells for Stroke 
(PISCES 1) trial administered ascending doses of human foetal neural stem cells that had been 
genetically modified with a c-mycER transgene to allow indefinite culture (58). No safety 
issues were identified with doses up to 20 million cells. The 20 million cell dose was taken 
forward into the PISCES-2 trial, a multicentre study that enrolled patients in the subacute 
recovery phase of ischaemic stroke at 3-12 months after the event; this trial reported 
improved upper limb motor recovery in sufficient numbers of subjects to warrant further 
investigation, based on an interim assessment after 3-6 months. The SanBio study (57) of 
modified donor bone marrow-derived mesenchymal stem cells was undertaken in 18 
subjects, and reported modest improvement in neurological function, as well as transient T2 
hyperintensities in peri-needle track locations in brain visualized with magnetic resonance 
imaging. No control groups were enrolled in either PISCES 1, PISCES 2 or the SanBio study, 
and no conclusions regarding efficacy are therefore possible. Selection of an appropriate 
control group for future trials poses both practical and ethical challenges (59,60), but placebo 
surgery using partial thickness burr holes to blind the study participants has been considered 
appropriate by trialists and regulators, and appears to be acceptable to patients. 
  The planned phase IIb European trial of intravenous injection of allogenic adipose-
derived stem cells (ADSC): Regenerative Stem Cell Therapy after Stroke in Europe (RESSTORE, 
www.resstore.eu) is a European multicenter translational trial (involving France, Spain, 
Finland, United Kingdom, Czech Republic) whose primary objective is to provide essential 
information on the therapeutic efficacy of allogenic ADSCs in stroke patients, following 
evaluation of safety and tolerability of this cell line. Several major concerns need to be taken 
in account in implementing a multicentre cell therapy trial i.e. standardization of cell 
manufacturing or processing in different sites according to regulatory agencies’ requirements, 
acquisition of sufficient safety data to guide dose selection and delivery methods, and 
appropriate study design with which to assess stroke recovery.  
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Study Design Issues to Assess Stroke Recovery 
In restorative studies, measuring recovery after stroke is challenging, and there is as yet no 
agreed approach (61). These problems are not unique to cell therapy, but reflect more general 
issues with rehabilitative or restorative approaches: cell therapy simply introduces additional 
constraints in terms of sample size limitations due to production issues, invasiveness of 
delivery, and more restrictive patient selection criteria. No clear distinction is often made 
between phase 2 and phase 3 studies, a failure evident from many neuroprotectant drug trials 
that sought to expedite development by blurring the distinctions between phase 2b and 
phase 3 trials, with a notable lack of success (62,63). Phase 2 studies should be concerned 
with exploring effect measures and finalizing dose selection, with the option of using 
biomarkers to provide valuable information about optimal trial design. Phase 2 studies also 
have the possibility of gathering more specific clinical measures to establish the biological 
evidence of an effect. Phase 3 studies are generally constrained by a need to establish efficacy 
using broader clinical measures of disability that may be less sensitive to change than more 
specific functional scales. They are usually undertaken in a multicenter setting where it may 
be difficult to obtain informative phenotypic data such as detailed imaging studies.      
The primary endpoint for phase 2 and 3 cell therapy trials has usually been based on 
a single validated general clinical scale such as the National Institutes of Health Stroke Score 
(NIHSS) or disability scale such as the modified Rankin Scale, although trials have adopted a 
range of different clinical measures, including specific motor function or domain-specific 
measures. Since the neurological deficits after stroke are usually multi-faceted and recovery 
a dynamic process, capturing the full picture of this process may require collection and 
analysis of multiple complementary measures at multiple time points (64). Beyond classical 
methods, recovery should be considered as a latent variable based on recent statistic 
methods developments such as structural equation modeling which has been shown to be 
applicable in pre-clinical and phase 2 clinical studies (61). There is a need to balance 
recruitment rates with the selected measurement tools; in general, a very specific motor 
outcome scale, such as the Action Research Arm Test (ARAT), may be more sensitive to change 
in the specific aspect of function that it is designed for than a general neurological scale, such 
as the NIHSS. Unfortunately, adopting a more specific scale places constraints on patient 
recruitment (65), since far fewer patients may have demonstrable deficits on that scale, and 
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the means of defining an improvement of true clinical value may be less clear. For small trials 
– inevitable in the cell therapy field – variance of an outcome measure should ideally be 
minimized by having the trial population as homogeneous as possible and selecting an 
outcome scale that has minimum inter-observer variability. While motor function recovery 
has commonly been selected as a human model system for phase 2 testing of rehabilitative 
and regenerative therapies, such a strategy for phase 3 efficacy trials may be deemed 
inadequate for allowing generalizable conclusions to be drawn. The modified Rankin Scale 
carries advantages of regulatory acceptability as a primary endpoint, wide understanding in 
the stroke community, availability of measures to minimize inter-observer variability such as 
structured interview approaches (66–68), independent video assessment (69), and availability 
of utility-weighted analyses that can facilitate health economic evaluation (70), and arguably 
it integrates the clinical effects in a globally meaningful way: improved ability to grasp a test 
object in the ARAT scale is of little value unless this translates into meaningful gains of day to 
day function. Nonetheless, the use of more specific motor recovery assessments is favored 
by rehabilitation specialists (71).  
Another goal of a large phase 3 trial is to validate the societal value and cost-
effectiveness (72) of a cell therapy based on health economics and predictive in silico (virtual 
population) models.  
As in animal studies, rehabilitation must be considered as a control “treatment” and 
ideally should be standardized to the extent that this is achievable. Harmonization of stroke 
rehabilitation is extremely difficult in practice due to inter-individual variation in patients’ 
individual deficits, prior functional level, and ability to participate. There have been wide 
variations in the delivery of “routine” rehabilitation both across and within different 
healthcare systems, and even documenting in a meaningful way the delivery of complex and 
individualized multi-dimensional rehabilitation is a major challenge. Self-directed therapy 
adds to the complexity. Data from diaries maintained by individual participants or their care-
givers may not be very reliable. Delivery of rehabilitation is also influenced by factors that 
may limit participation such as intercurrent infection, injury, or other medical therapy 
(including drugs that affect mood or alertness). As a minimum, different stroke centers should 
follow relevant guidelines, and document the quality and quantity of the rehabilitation 
program and ideally these factors could be included in statistical analyses as explanatory co-
variables. Rehabilitation literature increasingly suggests that time spent in activity matters 
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rather than specificity of therapy, and that there is no clear gain beyond a threshold of time 
spent (73). There is also a concern that more intensive therapy, at least at some stages where 
the brain may be vulnerable, is potentially harmful (74). In many trials of late stroke recovery, 
however, participants have been beyond the time frame for continued active rehabilitation 
provided by healthcare systems, and thus any ongoing rehabilitation may have been 
unstructured and personally funded. In many trials, wide variability in routine delivery of 
rehabilitation has led the trialists to adopt a strategy of prescribing some sessions of 
mandatory additional physiotherapy to all participants.  
Moreover, when studying the effects of a restorative therapy, in vivo biomarkers are 
essential when assessing the initial severity of the stroke; these may be important in patient 
selection, and may be relevant in following the recovery process. Clinical assessments can be 
correlated to biological and imaging markers. Several imaging markers may be of value in 
predicting the potential for motor recovery, for example,  task activation functional MRI (75), 
anatomical changes such as Wallerian degeneration (76) or thalamus damage (77), and the 
degree of corticospinal tract integrity (and excitability) (78–80). Nonetheless, it is far from 
straightforward to interpret changes over time in imaging parameters such as functional 
networks, task activation fMRI, or tract integrity, and furthermore there are often only limited 
statistical approaches to handling serial data of this kind.   
 
Regulatory Issues for Stem Cells Approval as a Medicinal Product 
Cell therapies are currently regulated as an Advanced Therapy Medicinal Product in the EU 
(81). This framework imposes additional regulatory requirements beyond those applied to 
clinical trials in general, including the requirement to have detailed information about the 
source of the biological agent, and to retain all documentation for a period of 30 years. 
Accrual of experience with cell products should ease ethical approval processes, but there 
remain unique issues in addition to the provenance of the cells. These include the culture 
media and potential for infectious agents present in cell culture to be passed on to the 
patient; the modification by transgene insertion of cell therapy agents, with a need to 
demonstrate lack of mutagenesis or other adverse effects; and the need to demonstrate the 
limits of cell viability after transport, storage, and any freezing or thawing procedures. 
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To harmonize cell manufacturing and quality controls in Europe, scientific advice from 
the European Medicinal Agency (EMA) is encouraged. To obtain a multi-country approval, 
regulatory agencies from each country involved in the trial will analyze the same dossier 
according to the Voluntary Harmonized Procedure (VHP). This process avoids the need for 
several national submissions and is intended to minimize the delay in initiating work in the 
clinical investigational centers in different countries. The scientific and regulation analysis 
concerns the cell source, culture media, cell stocks and final medicinal product being injected 
into the patient. A pathophysiological view including expected mechanism of action related 
to stroke is required, and this demands that a translational project must be linked to 
experimental (animal) data. Animal experiments must be conducted to provide safety/toxicity 
and biodistribution data and to potentially reveal mechanisms of action using appropriate 
biomarkers for subsequent patient follow-up (82). 
 
Summary and Conclusions 
Although experimental evidence for cell therapies is promising, an over-simplified study 
design without comorbid animals and a rehabilitation arm may result in the generation of too 
promising positive data. Multicenter studies are needed to mimic clinical reality and to take 
account of the heterogeneity of stroke patients; they also need to provide enough statistical 
power to allow the hard go/no go decision since this will eventually improve translation 
success. Progress on the clinical side has been slow and cautious, partly because of budgetary 
constraints. Now larger, randomized and controlled clinical trials are needed to reveal the 
efficacy of cell therapies in stroke patients. Since these will be multinational/multicenter 
trials, this will introduce challenges in organizing harmonized cell manufacturing in multiple 
sites and logistics in cell delivery. Careful patient selection, homogeneity and appropriate 
outcome measures might favor treatments effects (83).  
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Table 1. Cell sources and administration routes in preclinical and clinical stroke studies. 
 
 
     Preclinical   Clinical 
 
Studies included/subjects  306/5923   26/844 
Cell source 
 Autologous   10/340    18/134    
 Allogenic   150/2673   8/710 
 Syngeneic   5/131    - 
 Xenogeneic   146/2763   - 
 Unspecified   2/16    - 
Route of administration 
 Intra-arterial   33/551    6/57 
 Intravenous   156/3451   11/332 
 Intracerebral   109/1579   9/405 
 Intrathecal/ventricular 20/250    2/256 
  Others    4/92    - 
Data adapted from the recent clinical (84) and preclinical meta-analysis (Cui, in press).  
 
 Table 2. Completed clinical trials of cell therapy in stroke. 
 
 
Cases (age) Source Cell type Delay Dose Route Adverse events Country Ref 
12 IS 
(61 yr, 44-74) 
Human embryonic 
terato-carcinoma cell 
line (NT2/D1) 
LBS-Neurons  
(Layton BioSc.) 
2.5 years  
(7 months - 
4.5 years) 
2 (60 µL; n=8) or 6 
million (180 µL; n=4) 
+ Cyclosporine 
IC 1 single seizure at 6 months 
1 remote stroke at 5 
months 
Pittsburgh 
USA 
(85) 
6 IS 
8 ICH 
(58 yr) 
4 controls:  
3 IS / 1 ICH (46 yr) 
Human embryonic 
terato-carcinoma cell 
line (NT2/D1) 
LBS-Neurons  
(Layton BioSc.) 
3.5 years (1-
5 years) 
5 (n=7) or 10 million 
(n=7) (250 µL) 
+ Cyclosporine 
IC 1 single post-operative 
seizure 
1 asymptomatic SDH 
Pittsburgh, 
Stanford 
USA 
(86) 
5 IS 
(25-52 yr) 
Primordial porcine 
striatum (lateral 
ganglionic eminence) 
+ antiMHC1 
pretreated 
LGE cells 
(Genvec) 
5 years (1.5-
10 years) 
1 million /cm3 of 
infarct 
50 (n=4) or 80 million 
(n=1) 
IC Adverse events: cortical 
vein occlusion, n=1; 
hyperglycemic seizures, 
n=1; both with MRI 
transient abnormalities. 
FDA termination 
Boston 
USA 
(87) 
7 IS 
3 ICH 
Immature nervous 
and hemopoietic 
tissues 
Immature cell 
(NSC) 
4-24 months 1 injection (n=5) 
2 injections (n=5) 
IThec 
(LP) 
transient meningeal 
syndrome 
Novosibirsk 
Russia 
(88) 
24 
 
(46 yr; 35-56) 
11 controls: 
6 IS / 5 ICH 
(55 yr) 
5 IS 
(63 yr; 54-72) 
25 controls 
(59 yr) 
Auto BM MSC 
Expansion in 
fetal calf serum 
4-5 and 7-9 
weeks 
50 million x 2 IV 
 
Suwon 
S. Korea 
(89) 
16 IS 
(65 +/-14 yr) 
36 controls 
(64 +/-12 yr) 
including the 
previous trial 
Auto BM 
Expansion in fetal calf 
serum 
MSC 
Expansion in 
fetal calf serum 
2.5-5 and 5-
9 weeks 
50 million x 2 IV 1 fever after first injection 
(no second injection) 
Safe (3-5 years follow-up) 
 
Suwon 
S. Korea 
(90) 
1 IS 
(54 yr) 
Auto BM MNC 4 days 300 million (3 mL / 10 
min) 
IA 
 
Rio 
Brazil 
(91) 
3 IS 
(53-64 yr) 
2 ICH 
Auto BM MNC 3-8 years 14-55 million 
(115-220 µL) 
IC 5 headache 
2 drowsiness 
Habana 
Cuba 
(92) 
25 
 
(41 and 44 yr) 
6 IS  
(24-65 yr) 
Auto BM MNC 2-3 months 125-500 million 
including 20 million 
99mTc-labeled 
IA Biodistribution in brain, 
liver, lungs, spleen, 
kidneys, bladder 
Rio 
Brazil 
(93) 
(94) 
10 IS 
(55 +/-15 yr) 
79 historical 
controls 
(63 +/-12 yr) 
Auto BM MNC 1-3 days 7 (n=1) or 8.5 (n=1) or 
10 million /kg 
IV 1 death from pulmonary 
embolism at 40 days 
Houston 
USA 
(95) 
12 IS  
(59 yr, 41-73) 
Auto BM MSC 
Expansion in 
autologous 
serum 
10 weeks (5-
19 weeks) 
110 million (60-160 
million) 
IV 1 transient fever Sapporo 
Japan 
(96) 
4 IS 
2 ICH 
(42 yr, 20-59) 
6 controls: 
5 IS / 1 ICH 
(46 yr) 
Auto BM MSC 
Expansion in 
animal serum-
free media 
9 months (7-
12 months) 
50-60 million IV 
 
New Delhi 
India 
(97) 
26 
 
18 IS 
2 ICH  
(45 +/-12 yr) 
20 controls: 
19 IS / 1 ICH 
(45 +/-10 yr) 
including the 
previous trial 
Auto BM MSC 
Expansion in 
animal serum-
free media 
MNC 
10 months 
3m-2y 
MSC: 50-60 million 
(n=6) 
MNC: 50-60 million 
(n=14) 
IV  
 
New Delhi 
India 
(98) 
11 IS  
(30-70 yr) 
Auto BM MNC 7-30 days 80 million IV Feasibility = 11/11 (target-
dose = 9/11) 
 
New Delhi 
India 
(99) 
10 IS  
(67 +/-14 yr) 
10 controls 
(67 +/- 13 yr) 
Auto BM MNC 6 days (5-9 
days) 
159 million IA 2 seizure at 3 months 
Increase of serum βNGF 
Sevilla 
Spain 
(82) 
20 IS  
(?) 
Auto BM MNC 3-7 days 220 million IA 
 
Porto Alegre 
Brazil 
(100) 
60 ICH  
(56 yr, 39-74) 
Auto BM MNC 6 days (5-7 
days)  
2.4-23 million (3.5mL) IC 5 transient fever 
1 lung cancer 
Shandong 
China 
 (101) 
27 
 
40 controls 
(56 yr, 35-72) 
 
15 IS 
15 controls 
(35–75 yr) 
Auto blood PBSC CD34+ 
(GCSF prior to 
blood sampling) 
Iron cell 
labelling 
6 months – 
5 years 
3–8 million  
(6.6 +/-1.8 in 750 µL) 
IC  Taichung 
Taiwan 
(102) 
58 IS 
62 controls 
(18-70 yr) 
Auto BM MNC 18 days 
(7-30) 
281 million 
(30-500) 
IV No benefit 
 
India (54) 
5 IS 
(45-75 yo) 
 
Auto BM HSC CD34+ 7 days 1.2-2.8 million IA 1 renal dysfunction 
 
London 
United Kingdom 
(103) 
24 IS or ICH Auto BM MNC Chronic ? IThec  Mumbai 
India 
(104) 
12 IS 
(20-75 yr) 
Auto BM MNC 7-10 days 250 million (25 mL of 
BM, n=6) 
340 million (50 mL of 
BM, n=6) 
IV  Osaka, Kobe 
Japan 
(105) 
28 
 
18 IS 
(61 yr, 33-75) 
Allo BM MSC 
transfected 
(Notch-1) 
SanBio SB623 
22 months 2.5 or 5 or 10 million 
(n=6/ group)  
IC 1 epileptic seizure 
1 asymptomatic SDH 
1 transient stroke 
1 urinary tract infection 
1 pneumopathy 
 
Stanford 
USA 
(57) 
11 IS 
(69 yr, 60-82) 
Human fetal  neuro-
epithelium  
NSC 
CTX0E03 
transfected 
(cMycERTAM) 
 
29 +/-14 
months 
2 (n=3) 
5 (n=3) 
10 (n=3) or 20 million 
(n=2) 
IC 1 asymptomatic extradural 
hematoma 
1 asymptomatic SDH 
 
Glasgow 
UK 
(56) 
67 IS (62 yo) 
62 controls 
(63 yr) 
Allo BM MAPC 
Multistem 
24 to 48 
hours 
1200 million IV 4 fever 
2 nausea 
 
Multicentric 
USA / UK 
(55) 
 
Auto: autologous; Allo: allogenic; BM: bone marrow; DTI: diffusion tensor imaging; 18FDG PET: 18-fluorodeoxyglucose positon emission tomography; HSC: 
hematopoietic stem cells; IA: intra-arterial; IC: intracerebral; ICH: intracerebral hemorrhage; IS: ischemic stroke; IThec: intrathecal; IV: intravenous; LP: lumbar 
puncture; MAPC: multipotent adult progenitor cells; MNC: mononuclear cells; MSC: mesenchymal stromal/stem cells; NSC: neural stem cells; PBSC: peripheral 
blood stem cells 
